Blockchain Registration Transaction Record

Investor Alert: Securities Fraud Lawsuit Filed Against Cassava Sciences, Inc.

A securities class action lawsuit has been filed against Cassava Sciences, Inc. by Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased Cassava securities. The complaint alleges that Cassava's drug, simufilam, was not effective in treating Alzheimer's Disease. Investors have until February 10, 2025, to participate in the lead plaintiff process.

This news matters as it highlights alleged misconduct by Cassava Sciences, Inc. and the opportunity for investors to seek legal recourse if they suffered losses. The outcome of this lawsuit could have significant implications for the company and its stakeholders, potentially impacting future investment decisions and the pharmaceutical industry as a whole.